KRISHGEN BioSystems

OUR REAGENTS, YOUR RESEARCH

360+ BIOSIMILARS ELISA



specific, validated assays for detection of monoclonal antibody drugs for pharmacokinetic studies and therapeutic drug monitoring

measure free, bound and total drug concentrations in serum and plasma

Learn more about our products:

www.krishgen.biz

kbiinfo@krishgen.com

KRISHGEN BioSystems
OUR REAGENTS, YOUR RESEARCH

At Krishgen, our dedicated team is focused on identifying and prioritizing the most relevant targets and the latest mAb or bsAb drugs in the pipeline to provide cutting-edge assay solutions.

From target discovery to IVD or clinical phase analysis, we can support you at every stage of your monoclonal antibody / biosimilar drug research with the right products for your needs. To ensure the best performance when possible, we test and validate our products in the most relevant models in both healthy and diseased tissue and assays.

The range of Pharmacokinetics (PK) ELISA Kits for the quantification of serum and plasma protein drug levels to provide accurate pharmacokinetic (PK) data that will help optimize drug dosing regimens. These mAb-based ELISA are developed for use with biosimilars and biologics.

Popular ELISA for Pharmacokinetic (PK) and Anti-Drug Antibody Estimation

ANTI-TNF ALPHA AND INFLAMMATION BLOCKER MABS

INFLIXIMAB
ETANERCEPT
CERTOLIZUMAB
USTEKINUMAB
NATALIZUMAB
VEDOLIZUMAB
ADALIMUMAB
GOLIMUMAB
VEDOLIZUMAB
TOCILIZUMAB
ALEMTUZUMAB

ANTI-CANCER MABS

BEVACIZUMAB
TRASTUZUMAB
DARATUMUMAB
PANITUMUMAB
RITUXIMAB
CETUXIMAB
OBINUTUZUMAB

IMMUNE CHECKPOINT BLOCKER MABS (PD-1, PD-L1, CTLA4)

ATEZOLIZUMAB
PEMBROLIZUMAB
DURVALUMAB
RELATLIMAB
IPILIMUMAB
NIVOLUMAB
TREMELIMUMAB
AVELUMAB

OSTEOPOROSIS MABS

DENOSUMAB

ANTI-ALERGEN MABS

OMALIZUMAB

AMD MABS

RANIBIZUMAB
BEVACIZUMAB

Other ELISA available from Krishgen:

- **Immune Checkpoint**
- **Bispecific Antibody**
- **Neutralizing Antibodies to mAbs**
- **Peptide Drugs**
- **Cytokine and Biomarker**
- **Antibody Drug Conjugates**
- **Neuro-Degenerative Markers**
- **GLP-1 Agonists**

- Krishgen mAb ELISA employ anti-idiotypic monoclonal antibodies in a sandwich assay format, ensuring exceptional specificity and sensitivity in drug detection, even at low concentrations.
- All validation, verification and lot releases for these ELISA are performed according to best-in-class scientific guidelines (ICH M10, version July 2022) – including a stringent seven-point validation to ensure quality and robustness lot-over-lot.
- Where available, validation of the kit against international standards from NIBSC / WHO.
- To ensure no matrix interference and reproducible dilutional linearity, we run several serum and plasma spiking experiments at various dilutions to optimize. Inter and intra assay CV in accordance with FDA & EMEA requirements CV <10%.
- Ship at ambient temperature, with lyophilized / stabilized reagents.

International Organization for Standardization ISO 13485 Quality Management System

Our manufacturing lab is ISO 13485 and CDSCO (India) certified, with Class 7 / Class 8 cleanrooms and Air Handling Units to reduce contamination. Automated plate coating lines and handling equipment further reduce lot variation.

POPULAR PUBLICATIONS USING KRISHGEN PK ELISA


JAMA Oncology | Brief Report

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma

Chan Kim, MD, PhD; Hannah Yang, PhD; Ehwan Kim, MD; Beodeul Kang, MD; Hyeyeong Kim, MD; Hyunho Kim, MD; Won Suk Lee, PhD; Sanghoon Jung, MD; Ho Yeong Lim, MD, PhD; Jaekyung Cheon, MD; Hong Jae Chon, MD, PhD

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma

Atezolizumab ELISA


OPEN

The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease

Doaa Anbarserry[1], Mahmoud Mosli[2,4,7], Yousef Qari[2,4,7], Omar Saadah[3,4,7], Rana Bokhary[4,5,7], Ahmed Esmat[1], Mohammed Alsieni[1], Ahmed Shaker[1], Ramu Elango[6] & Sameer Alharthi[4,5]

The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease.

Vedolizumab ELISA


ELSEVIER

Carbohydrate Polymers
Volume 267, 1 September 2021, 118217

Chitosan coated nanoparticles for efficient delivery of bevacizumab in the posterior ocular tissues via subconjunctival administration

Jayamanti Pandit, Yasmin Sultana

Show more

Add to Mendeley Share

https://doi.org/10.1016/j.carbpol.2021.11821

Abstract

Chitosan coated nanoparticles for efficient delivery of bevacizumab in the posterior ocular tissues via subconjunctival administration.

Bevacizumab ELISA


Retina

Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits

Duygu Cam, Ayse Tulin Berk, Serap Cilaker Micili, Tuncay Kume, Bekir Ugur Ergur & Osman Yilmaz

Download citation https://doi.org/10.3109/02713683.2016.1164190

Full Article Figures & data References Citations Metrics Reprints & Permissions Read this article

ABSTRACT

Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.

Ranibizumab ELISA


A Prospective, Randomized, Double-blind, Comparative Clinical Study of Efficacy and Safety of a Biosimilar Adalimumab with Innovator Product in Patients with Active Rheumatoid Arthritis on a Stable Dose of Methotrexate

Prasad Apsangikar, Sunil Chaudhry, Manoj Naik, Shashank Deoghare[1], Jamila Joseph[1]

Medical Affairs Group, Clinical Research Group, Reliance Life Sciences, Navi Mumbai, Maharashtra, India

Received: September, 2017
Accepted: December, 2017
Published: May, 2018

Abstract

Introduction

A Prospective, Randomized, Double-blind, Comparative Clinical Study of Efficacy and Safety of a Biosimilar Adalimumab with Innovator Product in Patients with Active Rheumatoid Arthritis on a Stable Dose of Methotrexate

Adalimumab ELISA


Published: 06 October 2021

Oral Delivery of Peptide Formulations and Their Cellular Evaluation

Saurabh Patil, Kritika Gupta, Ashish Pandit, Bhushan Desai, Siegfried Gschliesser, Prajakta Dandekar & Ratnesh Jain

International Journal of Peptide Research and Therapeutics 27, 2831–2844 (2021) | Cite this article

354 Accesses | Metrics

Abstract

Oral Delivery of Peptide Formulations and Their Cellular Evaluation.

Liraglutide ELISA

KRISHGEN ELISA HAVE BEEN FEATURED IN 1500+ PUBLICATIONS IN JOURNALS AROUND THE WORLD.

View them on our website:

DIDN'T FIND WHAT YOU'RE LOOKING FOR?

Krishgen manufactures 20,000+ ELISA across more than 10 species. Talk to our technical team to find the right product for you at **kbiinfo@krishgen.com.**

Or, get in touch with us to custom develop your assay. Our custom services can help designing and producing sensitive, validated kits for your target(s) of interest.

For more information, please reach out to us at **services@krishgen.com**.

KRISHGEN BioSystems

OUR REAGENTS, YOUR RESEARCH

www.krishgen.biz | kbiinfo@krishgen.com | +1 (562)-568-5005 | +91 22 49198700
11331, 183rd Street, #431, Cerritos, CA 90703
Unit Nos#318/319, Shah & Nahar, Off Dr E Moses Road, Worli, Mumbai 400018